Contribution of Dolutegravir to Obesity and Cardiovascular Disease

NCT04340388 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

HIV-1-infection
Antiviral Drug Adverse Reaction
Vascular Diseases
Cardiovascular Abnormalities
Abnormality of Adipose Tissue
Body Weight Changes
Body Fat Disorder
HIV-Associated Lipodystrophy Syndrome

Interventions

DRUG: Dolutegravir 50 MG
DRUG: Antiretroviral/Anti HIV

Sponsor

Augusta University